Literature DB >> 641214

Clinica, pharmacology of tetrahydrouridine.

D H Ho, G P Bodey, S W Hall, R S Benjamin, N S Brown, E J Freireich, T L Loo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 641214     DOI： 10.1002/j.1552-4604.1978.tb02444.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  6 in total

1.  Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.

Authors:  Donald Lavelle; Kestis Vaitkus; Yonghua Ling; Maria A Ruiz; Reda Mahfouz; Kwok Peng Ng; Soledad Negrotto; Nicola Smith; Pramod Terse; Kory J Engelke; Joseph Covey; Kenneth K Chan; Joseph Desimone; Yogen Saunthararajah
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

2.  Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.

Authors:  Jan H Beumer; Julie L Eiseman; Judith A Gilbert; Julianne L Holleran; Archibong E Yellow-Duke; Dana M Clausen; David Z D'Argenio; Matthew M Ames; Pamela A Hershberger; Robert A Parise; Lihua Bai; Joseph M Covey; Merrill J Egorin
Journal:  Cancer Chemother Pharmacol       Date:  2010-05-05       Impact factor: 3.333

Review 3.  Fetal Hemoglobin Induction by Epigenetic Drugs.

Authors:  Donald Lavelle; James Douglas Engel; Yogen Saunthararajah
Journal:  Semin Hematol       Date:  2018-04-22       Impact factor: 3.851

4.  Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.

Authors:  Jan H Beumer; Julie L Eiseman; Robert A Parise; Jeffry A Florian; Erin Joseph; David Z D'Argenio; Robert S Parker; Brittany Kay; Joseph M Covey; Merrill J Egorin
Journal:  Cancer Chemother Pharmacol       Date:  2007-11-15       Impact factor: 3.333

5.  High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects.

Authors:  Quteba Ebrahem; Reda Z Mahfouz; Kwok Peng Ng; Yogen Saunthararajah
Journal:  Oncotarget       Date:  2012-10

6.  Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.

Authors:  Robert Molokie; Donald Lavelle; Michel Gowhari; Michael Pacini; Lani Krauz; Johara Hassan; Vinzon Ibanez; Maria A Ruiz; Kwok Peng Ng; Philip Woost; Tomas Radivoyevitch; Daisy Pacelli; Sherry Fada; Matthew Rump; Matthew Hsieh; John F Tisdale; James Jacobberger; Mitch Phelps; James Douglas Engel; Santhosh Saraf; Lewis L Hsu; Victor Gordeuk; Joseph DeSimone; Yogen Saunthararajah
Journal:  PLoS Med       Date:  2017-09-07       Impact factor: 11.069
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.